MedTrace Logo

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00252148 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2013-02-11

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of an immune response to an investigational HIV vaccine, ADMVA, at three different dosage levels, in adults who are not infected with HIV

Conditions

  • HIV Infection

Interventions

BIOLOGICAL

ADMVA

experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat

Sponsors & Collaborators

  • Aaron Diamond AIDS Research Center

    collaborator OTHER

  • University of Rochester

    collaborator OTHER

  • International AIDS Vaccine Initiative

    lead NETWORK

Principal Investigators

  • David Ho, MD · Aaron Diamond AIDS Research Center

  • Michael Keefer, MD · University of Rochester

  • Soe Than, MD · International AIDS Vaccine Initiative

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252148 on ClinicalTrials.gov